Answers are grounded in this paper and cite their sources.
This study aims to investigate differences in survival between current and former smokers receiving second-line or later nivolumab treatment for metastatic non-small cell lung cancer. This retrospective, observational study involved 544 patients from eight centres who were treated with nivolumab for non-small cell lung cancer (NSCLC) between January 2020 and January 2025. The median age was 63 (57–68), and 477 patients (87.7%) were male. The most common pathological subtype in 294 (54%) patients was adenocarcinoma. 184 (33.8%) patients were current smokers, while 320 (58.8%) patients were former smokers.The median progression-free survival (PFS) was 6.3 (5.2–7.5) months in current smokers, 11.6 (9.9–13.3) months in former smokers, and 9.4 (5.4–13.4) months in never smokers (p <0.001). The median overall survival (OS) was 8.4 (7.2–9.7) months in current smokers, 13 (11.5–14.5) months in former smokers, and 13.3 (9–17.5) months in never smokers (p <0.001). Multivariate Cox regression analysis was performed for factors affecting overall survival. Compared to current smokers, former smokers had a hazard ratio (HR) of 0.64 (95% confidence interval (CI): 0.50–0.83, p=0.001), indicating a reduced risk of mortality. In this multicenter retrospective cohort of patients with metastatic NSCLC receiving second-line or later nivolumab treatment, current smoking was associated with shorter progression-free and overall survival compared with former smoking. These findings highlight the importance of distinguishing current from former smokers when evaluating survival outcomes in patients receiving immunotherapy. Not applicable.
No takes yet. Share an insight, caveat, or question.
Oruç et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: